(Q56786918)

English

A phase II study of irinotecan plus cisplatin for patients with advanced stage IIIB or IV NSCLC previously treated with nonplatinum-based chemotherapy

No description defined

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

0 references

A phase II study of irinotecan plus cisplatin for patients with advanced stage IIIB or IV NSCLC previously treated with nonplatinum-based chemotherapy (English)

0 references

1 reference

based on heuristic

inferred from title

non-small-cell lung carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Heung T Kim

1

0 references

Ji-Youn Han

2

0 references

Dae H Lee

3

0 references

Jong H Chun

4

0 references

Hong G Lee

5

0 references

Jae J Lee

6

0 references

Hyae Y Kim

7

0 references

Sung Y Lee

8

0 references

Jin S Lee

9

0 references

language of work or name

0 references

publication date

15 August 2006

0 references

0 references

107

0 references

4

0 references

799-805

0 references

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22063

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22063

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22063

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22063

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22063

7 January 2021

based on heuristic

inferred from DOI database lookup

The importance of dose intensity in chemotherapy of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22063

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22063

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22063

7 January 2021

based on heuristic

inferred from DOI database lookup

Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicentre phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22063

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized Phase II study of two opposite administration sequences of irinotecan and cisplatin in patients with advanced nonsmall cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22063

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22063

7 January 2021

based on heuristic

inferred from DOI database lookup

Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22063

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.22063

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q56786918&oldid=1812075890"